Tracker › Companies › Foghorn Therapeutics Inc.
3 No sign of it. We found no public evidence tying Foghorn Therapeutics Inc.'s cuts to AI.
Every tracked 2026 layoff at Foghorn Therapeutics Inc., newest first. Scores are 0–100: how strongly the public evidence ties the cuts to AI. Sources are linked on each one.
AI score 3/100 (Minimal) · 80% interval 2–3 · evidence grade D · US · Pharma / Chemicals
Stated reason: On September 25, 2026, following review of clinical data from the Phase 1 trial of FHD-909, Foghorn Therapeutics Inc. (the “Company”) and Eli Lilly and Company (“Lilly”) made the decision not to advance the trial into the expansion phase. Further collaboration activities pursuant to the collaboration agreement between the Company and Lilly are not anticipated. As a result, Foghorn is prioritizing resources toward the…
Why 3: Plant, store or site closure · Drivers: contrary evidence −0.7, industry AI exposure +0.5
Evidence: SEC filing. Signals: attribution 0.0, primary source 0.0, exec statement 0.0, role exposure 0.455, industry exposure 0.712, AI investment 0.0, contrary evidence 0.4 · named roles: Nursing Assistants, Registered Nurses
Headcount basis: 8-K text
Scores are evidence-based estimates from a published model, not findings that AI caused any layoff. Spot something wrong or missing? Tell us.
Other Health Care & Pharma layoffs we track.
Health Care & Pharma · 3,800 workers
Health Care & Pharma · 648 workers
Health Care & Pharma · 419 workers
Health Care & Pharma · 365 workers
Health Care & Pharma · 300 workers
Health Care & Pharma · 120 workers
